DE69920888D1 - Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren - Google Patents

Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren

Info

Publication number
DE69920888D1
DE69920888D1 DE69920888T DE69920888T DE69920888D1 DE 69920888 D1 DE69920888 D1 DE 69920888D1 DE 69920888 T DE69920888 T DE 69920888T DE 69920888 T DE69920888 T DE 69920888T DE 69920888 D1 DE69920888 D1 DE 69920888D1
Authority
DE
Germany
Prior art keywords
inhibitors
factor
triazoline
pyrazoline
disubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69920888T
Other languages
English (en)
Other versions
DE69920888T2 (de
Inventor
J Pinto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of DE69920888D1 publication Critical patent/DE69920888D1/de
Application granted granted Critical
Publication of DE69920888T2 publication Critical patent/DE69920888T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Manufacturing Of Printed Wiring (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69920888T 1998-03-27 1999-03-23 Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren Expired - Fee Related DE69920888T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7972598P 1998-03-27 1998-03-27
US79725P 1998-03-27
PCT/US1999/006310 WO1999050255A2 (en) 1998-03-27 1999-03-23 Disubstituted pyrazolines and triazolines as factor xa inhibitors

Publications (2)

Publication Number Publication Date
DE69920888D1 true DE69920888D1 (de) 2004-11-11
DE69920888T2 DE69920888T2 (de) 2006-02-02

Family

ID=22152402

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69920888T Expired - Fee Related DE69920888T2 (de) 1998-03-27 1999-03-23 Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren

Country Status (9)

Country Link
US (3) US6191159B1 (de)
EP (1) EP1064270B1 (de)
JP (1) JP2002509924A (de)
AT (1) ATE278673T1 (de)
AU (1) AU3110999A (de)
CA (1) CA2321538A1 (de)
DE (1) DE69920888T2 (de)
ES (1) ES2230841T3 (de)
WO (1) WO1999050255A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69920888T2 (de) 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
DE69921358T2 (de) * 1998-12-23 2006-03-09 Bristol-Myers Squibb Pharma Co. Stickstoffhaltige heterobicyclen als faktor-xa-hemmer
US6858616B2 (en) 1998-12-23 2005-02-22 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor Xa inhibitors
AU4307800A (en) * 1999-04-30 2000-11-17 Merab Lomia New indication for use of antiepileptic agents and medicines
US6329527B1 (en) 1999-10-21 2001-12-11 Bristol-Myers Squibb Pharma Company Synthesis of 1,3,5-trisubstituted pyrazoles
EP1296982B1 (de) 2000-06-23 2007-09-19 Bristol-Myers Squibb Pharma Company 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AR035533A1 (es) 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
MXPA04002573A (es) 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7312214B2 (en) 2002-05-10 2007-12-25 Bristol-Myers Squibb Company 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors
US20050256130A1 (en) * 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) * 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) * 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
WO2004043457A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
CA2517572C (en) * 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (de) * 2003-03-07 2008-08-27 Schering Corporation Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7235662B2 (en) * 2003-06-11 2007-06-26 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7435831B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
TWI357901B (en) * 2004-03-12 2012-02-11 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivati
CA2647423C (en) 2006-03-24 2015-02-17 Eisai R&D Management Co., Ltd. Triazolone derivative
RU2430095C2 (ru) * 2006-03-24 2011-09-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производное триазолона
WO2009038157A1 (ja) * 2007-09-21 2009-03-26 Eisai R & D Management Co., Ltd. ２，３－ジヒドロ－イミノイソインドール誘導体
RU2557908C1 (ru) * 2014-07-04 2015-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" Способ инкубации куриных яиц
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5424334A (en) * 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US5550147A (en) 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
DE69411584T2 (de) * 1993-11-24 1998-12-17 The Du Pont Merck Pharmaceutical Co., Wilmington, Del. Isoxazoline derivate anwendbar als fibrinogen rezeptor antagonisten
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
BR9408137A (pt) * 1993-11-24 1997-08-12 Du Pont Merck Pharma Composto éster de prodroga método de tratamento composição farmacêutica e método de inibição
US5563158A (en) 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
DE69632548T2 (de) * 1995-12-21 2005-06-02 Bristol-Myers Squibb Pharma Co. ISOXAZOLIN, ISOTHIAZOLIN UND PYRAZOLIN ALS FAKTOR Xa INHIBITOREN
DE69717268T2 (de) * 1996-02-22 2003-09-04 Bristol-Myers Squibb Pharma Co., Wilmington M-amidinophenyl-analoga als faktor-xa-inhibitoren
WO1997047299A1 (en) * 1996-06-12 1997-12-18 3-Dimensional Pharmaceuticals, Inc. Amidino and guanidino heterocyclic protease inhibitors
CN1246847A (zh) * 1996-12-23 2000-03-08 杜邦药品公司 作为Xa因子抑制剂的含氮杂芳族化合物
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
WO1998057934A1 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company (AMIDINO)6-MEMBERED AROMATICS AS FACTOR Xa INHIBITORS
KR20010013977A (ko) * 1997-06-19 2001-02-26 블레어 큐. 퍼거슨 중성 ｐ1 특이성 기를 갖는 인자 ｘａ의 억제제
DE69920888T2 (de) * 1998-03-27 2006-02-02 Bristol-Myers Squibb Pharma Co. Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren

Also Published As

Publication number Publication date
WO1999050255A3 (en) 1999-11-18
JP2002509924A (ja) 2002-04-02
DE69920888T2 (de) 2006-02-02
US6191159B1 (en) 2001-02-20
US20030105105A1 (en) 2003-06-05
ES2230841T3 (es) 2005-05-01
CA2321538A1 (en) 1999-10-07
US6436985B2 (en) 2002-08-20
EP1064270B1 (de) 2004-10-06
AU3110999A (en) 1999-10-18
ATE278673T1 (de) 2004-10-15
EP1064270A2 (de) 2001-01-03
WO1999050255A2 (en) 1999-10-07
US20010000179A1 (en) 2001-04-05
US6630468B2 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
DE69920888D1 (de) Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
DE60003025D1 (en) Arylsulfonyle als faktor xa inhibitoren
DE60130555D1 (de) 1-(heteroaryl-phenyl)-kondensierte pyrazol-derivate als factor xa inhibitoren
ATE193883T1 (de) Verbindungen und ihre zusammensetzungen mit entzündungshemmenden und anti-thrombotischen wirkungen
DE69718194D1 (de) Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate
DE60324544D1 (de) Muskarin antagonisten
NO20021395L (no) Kinazolinderivater
PT1204323E (pt) Fungicidas
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
GB9803228D0 (en) Chemical compounds
MXPA03006483A (es) Derivados de fenilo.
MXPA05010652A (es) Pirazoles sustituidos.
ATE227277T1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
DK0998460T3 (da) Hidtil ukendte tetrazolderivater
ATE217889T1 (de) Humane antikörper gegen faktor ix/ixa
DE50113345D1 (de) Arginin-mimetika als faktor xa-inhibitoren
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
BG105710A (en) 5ht1 antagonists for antidepressant therapy
ATE287403T1 (de) 6-phenylbenzonaphthyidine
ATE230718T1 (de) Beta-alkoxyacrylate gegen malaria
ATE276259T1 (de) Dihydroporphyrinderivate und ihre verwendung
DE60224805D1 (de) 1-glycinyl-4-(1-methylpiperidin-4-yl)piperazine un
ATE364594T1 (de) (4-acylaminopiperidin-1-yl)acetamide als neurokininantagonisten
MXPA05013035A (es) Derivados de aroilsemicarbazida.
ATE273302T1 (de) Diazocinderivate und deren verwendung als tryptase inhibitoren

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee